Discovery of YYSW001: A Highly Selective, Orally Bioavailable JAK1 Inhibitor Achieving Efficacy under a Moderate-Inhibition Strategy with Improved Preclinical Tolerability

求助中 10 由老满足了发布于 2026/5/24 18:22:34

DOI:10.1021/acs.jmedchem.5c03183
作者：Kaiyong Hu, , , Yezhi Wang, , , Pengfei Xu, , , Tian Jing, , , Xinying Cheng, , , Pei Shen, , , Baoxin Wang, , , Kang Fu, , ,
文献类型：期刊论文
补充材料：只需要正文

American Chemical Society (ACS)

Abstract：Janus kinase 1 (JAK1)-preferential inhibition has emerged as a promising approach to maintain anti-inflammatory efficacy while minimizing hematopoietic adverse effects attributed to JAK2 blo

应助信息

等您来应助

上传文件

11小时前

Book学术机器人

2026/5/24 18:22:34 未找到该文献，机器人已退出，请等待人工下载

2026/5/24 18:22:34 Book学术AI机器人收到请求，开始寻找文献

2026/5/24 18:22:34 已向机器人发送请求

11小时前

老满足了发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:SpringerA Meta-Analysis of Friends with Benefits Relationships: Examining Sexual Features, Sexual and Mental Health, Violence/Aggression, and Gender